Motley Fool Wealth Management LLC Increases Stock Position in DexCom, Inc. $DXCM

Motley Fool Wealth Management LLC lifted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 26.8% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 276,495 shares of the medical device company’s stock after purchasing an additional 58,495 shares during the period. DexCom comprises 1.4% of Motley Fool Wealth Management LLC’s holdings, making the stock its 18th biggest position. Motley Fool Wealth Management LLC’s holdings in DexCom were worth $18,351,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of DXCM. Brighton Jones LLC lifted its position in shares of DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after purchasing an additional 11,946 shares during the period. Integrated Wealth Concepts LLC lifted its position in shares of DexCom by 6.3% in the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after purchasing an additional 196 shares during the period. Empowered Funds LLC lifted its position in shares of DexCom by 5.4% in the 1st quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock worth $577,000 after purchasing an additional 436 shares during the period. Focus Partners Wealth lifted its position in shares of DexCom by 13.2% in the 1st quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock worth $493,000 after purchasing an additional 841 shares during the period. Finally, NewEdge Advisors LLC lifted its position in shares of DexCom by 1.4% in the 2nd quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock worth $1,681,000 after purchasing an additional 258 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on DXCM. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of DexCom in a research report on Monday, June 1st. Mizuho set a $85.00 price objective on shares of DexCom and gave the stock an “outperform” rating in a research note on Tuesday. Barclays reiterated an “underweight” rating and set a $64.00 price objective (down from $67.00) on shares of DexCom in a research note on Monday, May 18th. Sanford C. Bernstein set a $77.00 price objective on shares of DexCom in a research note on Friday, May 1st. Finally, Benchmark started coverage on shares of DexCom in a research note on Monday, May 11th. They set a “buy” rating and a $77.00 price objective for the company. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $83.46.

Insider Activity at DexCom

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total value of $107,168.00. Following the completion of the transaction, the executive vice president owned 111,204 shares of the company’s stock, valued at approximately $7,010,300.16. This trade represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of the firm’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the completion of the transaction, the insider directly owned 382,482 shares of the company’s stock, valued at approximately $27,538,704. This represents a 6.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 42,694 shares of company stock worth $3,029,267. Corporate insiders own 0.28% of the company’s stock.

DexCom Stock Performance

DXCM opened at $78.19 on Wednesday. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $89.98. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. The company has a market cap of $30.17 billion, a P/E ratio of 33.41, a price-to-earnings-growth ratio of 1.20 and a beta of 1.45. The firm’s 50-day moving average price is $65.36 and its 200-day moving average price is $67.28.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the prior year, the company posted $0.32 earnings per share. The company’s revenue for the quarter was up 15.0% compared to the same quarter last year. As a group, equities analysts anticipate that DexCom, Inc. will post 2.57 EPS for the current fiscal year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.